JOURNAL OF COSMETIC SCIENCE 82 IN DEPENDENT EVALUATOR DATA Ov erall appearance. Af ter 1 mo of using the topical product, 29.5% of SD had shown mild improvement, 34.1% had shown moderate improvement, 9.1% had shown sig- nifi cant improvement, 27.3% had no change in overall appearance, and none of the SD worsened. After 1 mo of no treatment, 29.5% of SD had shown mild improvement, 6.8% had shown moderate improvement, 61.4% had shown no change, 2.3% had worsened in overall appearance, and none had shown signifi cant improvement (Table VI, Figure 4). On average, 86.4% of SD that were treated with the topical product were rated as having better overall appearance by independent evaluators. On average, 0.0% of untreated SD Table V Patient-Reported Outcome, Average Scores for Tolerability Treatment Score (count), N = 22 patients Proportion (%), N = 22 patients 95% margin of error Topical product No issues 20/22 (90.9%) ±12.0% Mild issues 2/22 (9.1%) ±12.0% Moderate issues 0/22 (0.0%) ±0.0% Severe intolerance 0/22 (0.0%) ±0.0% No treatment No issues 22/22 (100.0%) ±0.0% Mild issues 0/22 (0.0%) ±0.0% Moderate issues 0/22 (0.0%) ±0.0% Severe intolerance 0/22 (0.0%) ±0.0% Figure 3. Patient reported a v erage scores for overall appearance of topically treated SD.

NEW TOPICAL SILICONE FORMULATION FOR TREATING STRIAE DISTENSAE 83 Table VI Evaluator Average Scores for Overall Appearance Treatment Score Proportion (%) N = 22 patients 95% margin of error Topical product Worsened 0/22 (0.0%) ±0.0% No change 6/22 (27.3%) ±13.2% Mild improvement 6.5/22 (29.5%) ±13.5% Moderate improvement 7.5/22 (34.1%) ±14.0% Signifi cant improvement 2/22 (9.1%) ±8.5% No treatment Worsened 0.5/22 (2.3%) ±4.4% No change 13.5/22 (61.4%) ±14.4% Mild improvement 6.5/22 (29.5%) ±13.5% Moderate improvement 1.5/22 (6.8%) ±7.4% Signifi cant improvement 0/22 (0.0%) ±0.0% Figure 4. Evaluator overall a p pearance: Average distribution of scores. were rated as having better overall appearance. This was verifi ed to be a statistically sig- nifi cant difference by the Wilcoxon signed-rank test (Table VII, Figure 5). No adverse reactions were recorded over the duration of this study, and no patient discon- tinued the use of the topical product. DI SCUSSION Ba sed on evaluator grading, we saw improvement in 72.7% of treated SD over a period of 1 mo with our topical product. In addition, the majority of subjects (86.4%) indicated that they saw mild improvement or more to their treated SD (Figures 6–8). No subjects indicated a worsening in appearance of SD or intolerability of the product. Based on this study, the formulation was safe to use and well tolerated.